Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

AACR 2009: Preclinical Analysis of Combined PI3K and MEK Inhibition as a Strategy for the Treatment of Cancer

AACR 2009

18 - 22 Apr 2009

Published: 30 Apr 2009

Views: 16266

Rating:

Save

Dr Lori Friedman - Director, Cancer Signalling and Translational Oncology, Genentech

Lori S. Friedman, Ph.D., director, Cancer Signaling and Translational Oncology, Genentech gives a presentation at the 2009 AACR meeting in Denver on: Preclinical Analysis of Combined PI3K and MEK Inhibition as a Strategy for the Treatment of Cancer.

Related Videos

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

ASCO GU 2024: Latest in PARP inhibitors for prostate cancer

Dr Friederike Schlurmann, Dr Nabil Adra, Dr Emmanuel Antonarakis and Dr Hiroshi...

ASCO GU 2024: Latest in PARP inhibitors for prostate cancer ( Dr Friederike Schlurmann, Dr Nabil Adra, Dr Emmanuel Antonarakis and Dr Hiroshi Kitamura )

Updates on lung cancer from WCLC and ESMO 2023

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Updates on lung cancer from WCLC and ESMO 2023 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

Liquid biopsies and cancer: The role of NGS, CTC, exosomes, cfDNA and cfRNA

Dr Bruna Pellini - Moffitt Cancer Center, Tampa, USA

Liquid biopsies and cancer: The role of NGS, CTC, exosomes, cfDNA and cfRNA ( Dr Bruna Pellini - Moffitt Cancer Center, Tampa, USA )

Predictive and prognostic biomarkers for immunotherapy in lung cancer

Dr Ignacio Gil Bazo - Fundación Instituto Valenciano de Oncología (FIVO)...

Predictive and prognostic biomarkers for immunotherapy in lung cancer ( Dr Ignacio Gil Bazo - Fundación Instituto Valenciano de Oncología (FIVO), Valencia, Spain )

Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone...

Prof Meletios Dimopoulos - National and Kapodistrian University of Athens...

$Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma ( Prof Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece )$

Triplets for newly diagnosed unfit AML patients could be feasible with...

Dr Juan Miguel Bergua Burgues - Hospital San Pedro de Alcántara, Cáceres, Spain

Triplets for newly diagnosed unfit AML patients could be feasible with substantial venetoclax reduction ( Dr Juan Miguel Bergua Burgues - Hospital San Pedro de Alcántara, Cáceres, Spain )

Treatment sequencing for patients with mCRPC

Prof Axel Merseburger and Prof Stéphane Oudard

Treatment sequencing for patients with mCRPC ( Prof Axel Merseburger and Prof Stéphane Oudard )

More from ecancer